" class="no-js "lang="en-US"> Eric E. Whitaker - Medtech Alert
Sunday, October 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Eric E. Whitaker

Eric E. Whitaker

About Eric E. Whitaker

Dr. Eric E. Whitaker is trained in Primary Care Internal Medicine and Preventive Medicine, a health policy expert and licensed investment professional. Dr. Whitaker has served for more than 30 years in public and private roles to develop innovative healthcare solutions for medically underserved populations, with a focus on startups and technologies to improve operational efficiency and clinical outcomes.

Related Story

Appointments

 IT Veteran Vrajesh Shah Joins Zing Health as Chief Information Officer | Pharmtech Focus

IT Veteran Vrajesh Shah Joins Zing Health as Chief Information Officer

August 31 2021

Zing Health, a physician-led, tech-enabled Medicare Advantage plan focused on underserved communities, has named Vrajesh Shah as […]